A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia

BJU International

Volumn 106, Issue 5, 2010, Pages 674-680

  Tamimi, Nihad A M ^a   Mincik, Ivan ^b   Haughie, Scott ^a   Lamb, Janice ^a   Crossland, Anna ^a   Ellis, Peter ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Reiman Hospital   (Slovakia)

Author keywords

BPH; erectile function; IPSS; LUTS; maximum urinary flow rate; phosphodiesterase type 5 inhibitor

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; TAMSULOSIN; UK 369 003; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUSTRALIA; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; EUROPE; FLUSHING; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; NORTH AMERICA; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RHINOPHARYNGITIS; SIDE EFFECT; SOUTH AMERICA; TREATMENT OUTCOME; URINARY URGENCY; URINE FLOW RATE; URINE VOLUME;

ADULT; AGED; EPIDEMIOLOGIC METHODS; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHOSPHODIESTERASE INHIBITORS; PROSTATIC HYPERPLASIA; PROSTATISM; PYRIMIDINONES; QUALITY OF LIFE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77955896740     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09204.x     Document Type: Article

References (27)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984 132 : 474 9
2. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 61 : 37 49
3. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003 44 : 637 49
4. Barry MJ, Fowler FJ Jr., O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992 148 : 1549 57 discussion 64
5. Shapiro E, Lepor H. Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am 1995 22 : 285 90
6. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993 150 : 351 8
7. Koskimaki J, Hakama M, Huhtala H, Tammela TL. Association of non-urological diseases with lower urinary tract symptoms. Scand J Urol Nephrol 2001 35 : 377 81
8. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical 'Aging Male' symptoms? Results of the 'Cologne Male Survey. Eur Urol 2003 44 : 588 94
9. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008 101 : 1388 95
10. Sanchez-Cruz JJ, Cabrera-Leon A, Martin-Morales A, Fernandez A, Burgos R, Rejas J. Male erectile dysfunction and health-related quality of life. Eur Urol 2003 44 : 245 53
11. Sexton CC, Coyne KS, Kopp ZS et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden. Epiluts. BJU Int 2009 103 (Suppl. 3 12 23
12. McVary K. Lower urinary tract symptoms and sexual dysfunction. Epidemiology 2006 97 (Suppl. 2 23 8 discussion 44-5
13. Andersson KE, Persson K. Nitric oxide synthase and nitric oxide-mediated effects in lower urinary tract smooth muscles. World J Urol 1994 12 : 274 80
14. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006 98 : 1259 63
15. Toque HA, Antunes E, Teixeira CE, De Nucci G. Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra. Urology 2008 72 : 711 5
16. Wibberley A, Nunn PA, Naylor AM, Ramage AG. An investigation of the effects of zaprinast, a PDE inhibitor, on the nitrergic control of the urethra in anaesthetized female rats. Br J Pharmacol 2002 136 : 399 414
17. McVary KT, Monnig W, Camps JL Jr., Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007 177 : 1071 7
18. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007 177 : 1401 7
19. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008 180 : 1228 34
20. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008 53 : 1236 44
21. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999 11 : 319 26
22. Whitehead J, Valdes-Marquez E, Johnson P, Graham G. Bayesian sample size for exploratory clinical trials incorporating historical data. Stat Med 2008 27 : 2307 27
23. Smith MK, Jones I, Morris MF, Grieve AP, Tan K. Implementation of a Bayesian adaptive design in a proof of concept study. Pharm Stat 2006 5 : 39 50
24. Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995 154 : 1770 4
25. van Leeuwen JH, Castro R, Busse M, Bemelmans BL. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006 50 : 440 52 discussion 53
26. Guler C, Tuzel E, Dogantekin E, Kiziltepe G. Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol Int 2008 80 : 181 5
27. Giuliano F, Lamb J, Crossland A, Haughie S, Ellis PX, Tamimi NAM. A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. BJU Int 2010 [Epub ahead of print]